Amine PEG2 Propionic Acid

We offer a competitive price for kilogram-scale manufacture, please contact us for a quotation for NH2-PEG2-

PA (Amine PEG2 Propionic Acid), high purity PEG amino acid for ADCs.

SKU: NH2-PEG2-PA

Categories: Discrete Monodisperse PEGs, Heterobifunctional Monodisperse PEGs, PEG Linkers for ADCs,

PEGs WITH AMINE, PEGs with CARBOXYL, PROTAC Linkers, Small Molecule Reagents

Description

JenKem Technology provides large scale manufacture of high purity NH2-PEG2-PA (Amine PEG2 Propionic Acid) 

for Antibody Drug Conjugates (ADCs), PROTAC, and other applications, in both GMP and non-GMP grade. 

Please contact us at sales@jenkemusa.com to request a quotation for NH2-PEG2-PA (Amine PEG2 Propionic Acid).

The presence of PEG linkers between the antibody and payload can influence the properties1 of the ADCs:

Modulate the physicochemical properties, such as balance the payloads’ hydrophobicity, improve solubility,

increase DAR, and reduce aggregation

Modify the Pharmacodynamic properties, such as increase the rate of payload release and increase invitro 

cytotoxicity

Optimize the pharmacokinetic properties, such as clearance, half-life, and biodistribution

Visit https://jenkemusa.com/peg-products-for-adcs to learn more about our heterobifunctional monodisperse 

discrete PEGs, and multi-arm heterofunctional PEGs for ADCs.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively 

in the development and manufacturing of high-quality polyethylene glycol (PEG) products and derivatives, 

and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified 

and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to 

in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem 

Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, 

and emerging chemical specialty markets, from laboratory scale through large commercial scale.

References:

1 Giese, M. W., Woodman, R. H., Hermanson, G. T. & Davis, P. D. in Chemical Linkers in Antibody-Drug Conjugates 

(ADCs) 286-376 (The Royal Society of Chemistry, 2022).